Agios Pharmaceuticals (AGIO) Scheduled to Post Quarterly Earnings on Thursday

Agios Pharmaceuticals (NASDAQ:AGIO) will issue its quarterly earnings data before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of ($1.63) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.64) by ($0.08). Agios Pharmaceuticals had a negative net margin of 1,312.64% and a negative return on equity of 38.08%. The company had revenue of $7.10 million for the quarter, compared to the consensus estimate of $7.80 million. During the same period last year, the business earned $0.67 EPS. The firm’s quarterly revenue was up 65.1% on a year-over-year basis. On average, analysts expect Agios Pharmaceuticals to post $-5 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Agios Pharmaceuticals Trading Down 0.4 %

NASDAQ AGIO opened at $31.67 on Thursday. Agios Pharmaceuticals has a 12 month low of $19.80 and a 12 month high of $35.50. The stock’s fifty day moving average price is $29.80 and its 200-day moving average price is $25.13. The stock has a market cap of $1.78 billion, a P/E ratio of -5.00 and a beta of 0.83.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, CEO Brian Goff sold 4,156 shares of the firm’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $32.57, for a total value of $135,360.92. Following the transaction, the chief executive officer now directly owns 53,780 shares in the company, valued at approximately $1,751,614.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, CEO Brian Goff sold 4,156 shares of the company’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $32.57, for a total transaction of $135,360.92. Following the completion of the sale, the chief executive officer now owns 53,780 shares of the company’s stock, valued at approximately $1,751,614.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider James William Burns sold 2,642 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $32.57, for a total transaction of $86,049.94. Following the sale, the insider now owns 34,518 shares of the company’s stock, valued at $1,124,251.26. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,035 shares of company stock worth $475,277. Insiders own 4.24% of the company’s stock.

Wall Street Analyst Weigh In

AGIO has been the topic of several recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, April 9th. JPMorgan Chase & Co. dropped their price objective on Agios Pharmaceuticals from $31.00 to $30.00 and set a “neutral” rating on the stock in a research report on Friday, February 23rd. Finally, Royal Bank of Canada decreased their target price on Agios Pharmaceuticals from $43.00 to $42.00 and set an “outperform” rating for the company in a research report on Friday, February 16th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, Agios Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $33.50.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.